Skip to main content

Advertisement

SpringerLink
Log in

Cytoreductive Surgery and Intraoperative Hyperthermic Intraperitoneal Chemotherapy with Paclitaxel: A Clinical and Pharmacokinetic Study

  • Gynecologic Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Intraperitoneal chemotherapy has been recommended as a treatment option for ovarian cancer with peritoneal dissemination. Although its treatment duration is significantly shorter, intraoperative hyperthermic intraperitoneal perfusion chemotherapy (HIPEC) has several advantages over simple intraperitoneal instillation chemotherapy. While platinum compounds have usually been used, only a few have administered paclitaxel during HIPEC. Its large molecular weight suggests a much more favorable pharmacokinetic profile than that of platinum compounds. The pharmacokinetics of paclitaxel during and after HIPEC have not been studied before.

Methods

Thirteen women, mainly with ovarian cancer, underwent cytoreductive surgery and HIPEC with 175 mg/m2 paclitaxel for 2 h. Morbidity was noted. Peritoneal fluid samples and blood samples were harvested during and until 5 days after HIPEC for pharmacokinetic study in ten patients.

Results

No treatment-related mortality was noted. Overall morbidity was 38% (two wound infections, one deep venous thrombosis, two grade 1 thrombopenia, one grade 2 neutropenia, and one grade 3 pancytopenia). Mean maximal intraperitoneal paclitaxel concentration was 101 mg/L, which was an average of 1178 times higher than the peak plasma levels. The peritoneal fluid versus plasma AUC ratio was 1462 for the 2-h HIPEC duration and 366 for the total 5-day study period. Cytotoxic drug concentrations were detected in peritoneal fluid for a mean period of 2.7 days, despite drainage of the drug solution after 2 h of treatment.

Conclusions

HIPEC with paclitaxel following cytoreductive surgery is feasible, relatively safe, and associated with a highly favorable pharmacokinetic profile, despite its short treatment duration. Larger studies with a more homogenous patient cohort and adequate follow-up should be performed to demonstrate its efficacy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.

Similar content being viewed by others

REFERENCES

  1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10–30

    PubMed  Google Scholar 

  2. McGuire WP III, Markman M. Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer 2003; 89 suppl 3:S3–8

    Article  PubMed  CAS  Google Scholar 

  3. Kyrgiou M, Salanti G, Pavlidis N, et al. Survival benefits with diverse chemotherapy regimens for ovarian cancer: a meta-analysis of multiple treatments. J Natl Cancer Inst 2006; 98:1655–63

    Article  PubMed  CAS  Google Scholar 

  4. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphomide for stage III ovarian cancer. New Engl J Med 1996; 335:150–5

    Article  Google Scholar 

  5. Markman M, Bundy B, Alberts DS, et al. Phase III study of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19:1001–7

    PubMed  CAS  Google Scholar 

  6. de Bree E, Theodoropoulos PA, Rosing H, et al. Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside. Cancer Treat Rev 2006; 32:471–82

    Article  PubMed  CAS  Google Scholar 

  7. Armstrong DK, Bundy BN, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New Eng J Med 2006; 354:34–43

    Article  PubMed  CAS  Google Scholar 

  8. Trimble EL, Christian MC. Intraperitoneal chemotherapy for women with advanced epithelial ovarian carcinoma. Gynecol Oncol 2006; 100:3–4

    Article  PubMed  Google Scholar 

  9. de Bree E, Tsiftsis DD. Principles of perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis. Recent Results Cancer Res 2007; 169:39–51

    PubMed  Google Scholar 

  10. Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: Tissue penetration and surface exposure. J Natl Cancer Inst 1997; 89:480–7

    Article  PubMed  CAS  Google Scholar 

  11. Witkamp AJ, de Bree E, van Goethem AR, et al. Rationale and technique of intraoperative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev 2001; 27:365–74

    Article  PubMed  CAS  Google Scholar 

  12. Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin North Am 2003; 12; 689–701

    Article  Google Scholar 

  13. Markman M. Intraperitoneal Taxol. Cancer Treat Res 1996; 81:1–5

    PubMed  CAS  Google Scholar 

  14. Markman M, Rowinsky E, Hakes T, et al. Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study. J Clin Oncol 1992; 10:1485–91

    PubMed  CAS  Google Scholar 

  15. Fushida S, Furui N, Kinami S, et al. [Pharmacologic study of intraperitoneal paclitaxel in gastric cancer with peritoneal dissemination]. Gan To Kagaku Ryoho 2002; 29:2164–7

    PubMed  Google Scholar 

  16. Hofstra LS, Bos AME, de Vries EGE, et al. Kinetic modelling and efficacy of intraperitoneal paclitaxel combined with intravenous cyclophosphamide and carboplatin as first-line treatment in ovarian cancer. Gynecol Oncol 2002; 85:517–23

    Article  PubMed  CAS  Google Scholar 

  17. Francis P, Rowinsky E, Schneider J, et al. Phase I feasibility and pharmacologic study of weekly paclitaxel: a Gynecologic Oncology Group pilot study. J Clin Oncol 1995; 13:2961–7

    PubMed  CAS  Google Scholar 

  18. Rupniak HY, Whelan RD, Hill BT. Concentration and time-dependent inter-relationships for antitumour drug cytotoxicities against tumour cells in vitro. Int J Cancer 1983; 32:7–12

    Article  PubMed  CAS  Google Scholar 

  19. Michalakis J, Georgatos SD, de Bree E, et al. Short term exposure of cancer cells to micromolar doses of paclitaxel, with or without hyperthermia, induces long term inhibition of cell proliferation and cell death in vitro. Ann Surg Oncol 2007; 14:1220–8

    Article  PubMed  Google Scholar 

  20. Michalakis J, Georgatos SD, Romanos J, et al. Micromolar taxol, with or without hyperthermia, induces mitotic catastrophe and cell necrosis in HeLa cells. Cancer Chemother Pharmacol 2005; 56:615–22

    Article  PubMed  CAS  Google Scholar 

  21. de Bree E, Rosing H, Beijnen JH, et al. Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer. Anticancer Drugs 2003; 14:103–10

    Article  PubMed  Google Scholar 

  22. de Bree E, Romanos J, Michalakis J, et al. Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin. Anticancer Res 2003; 23:3019–28

    PubMed  Google Scholar 

  23. Tsiftsis D, de Bree E, Romanos J, et al. Peritoneal expansion by artificially produced ascites during perfusion chemotherapy. Arch Surg 1999; 134:545–9

    Article  PubMed  CAS  Google Scholar 

  24. Stokvis E, Ouwehand M, Nan LG, et al. A simple and sensitive assay for the quantificative analysis of paclitaxel in human and mouse plasma and brain tumor tissue using coupled liquid chromatography and tandem mass spectrometry. J Mass Spectrom 2004; 39:1506–12

    Article  PubMed  CAS  Google Scholar 

  25. Wiernik PH, Schwartz EL, Strauman JJ, et al. Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987; 47:2486–93

    PubMed  CAS  Google Scholar 

  26. Kohn EC, Sarosy G, Bicher A, et al. Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 1994; 86:18–24

    Article  PubMed  CAS  Google Scholar 

  27. Omura GA, Brady MF, Look KY, et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an Intergroup study. J Clin Oncol 2003; 21:2843–8

    Article  PubMed  CAS  Google Scholar 

  28. Reed E, Bitton R, Sarosy G, et al. Paclitaxel dose intensity. J Infus Chemother 1996; 6:59–63

    PubMed  CAS  Google Scholar 

  29. Takimoto CH, Rowinsky EK. Dose-intense paclitaxel: déjà vu all over again? J Clin Oncol 2003; 21; 2810–4

    Article  PubMed  CAS  Google Scholar 

  30. Mohamed F, Marchetti P, Stuart OA, et al. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions. Cancer Chemother Pharmacol 2003; 52:405–10

    Article  PubMed  CAS  Google Scholar 

  31. Innocenti F, Danesi R, Di Paolo A, et al. Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice. Drug Metab Dispos 1995; 23:713–7

    PubMed  CAS  Google Scholar 

  32. Ohashi N, Kodera Y, Nakanishi H, et al. Efficacy of intraperitoneal chemotherapy with paclitaxel targeting peritoneal micrometastases as revealed by GFP-tagged human gastric cancer cell lines in nude mice. Int J Oncol 2005; 27:637–44

    PubMed  CAS  Google Scholar 

  33. Kuh H-J, Jang S, Wientjes JM, et al. Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exper Ther 1999; 290:871–80

    CAS  Google Scholar 

  34. Mohamed F, Marchetti P, Stuart OA, et al. A comparison of hetastarch and peritoneal dialysis solution for intraperitoneal chemotherapy delivery. Eur J Surg Oncol 2003; 29:261–5

    Article  PubMed  CAS  Google Scholar 

  35. de Bree E, Tsiftsis DD. Experimental and pharmacokinetic studies in intraperitoneal chemotherapy: from laboratory bench to bedside. Recent Results Cancer Res 2007; 169:53–73

    PubMed  Google Scholar 

  36. Fushida S, Nao F, Kinami S, et al. [Pharmacologic study of intraperitoneal docetaxel in gastric cancer with peritoneal dissemination]. Gan To Kagaku Ryoho 2002; 29:1759–63

    PubMed  Google Scholar 

  37. Morgan RJ, Doroshow JH, Synold T, et al. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Clin Cancer Res 2003; 9:5896–901

    PubMed  CAS  Google Scholar 

  38. Yokogawa K, Jin M, Furui N, et al. Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles. J Pharm Pharmacol 2004; 56:629–34

    Article  PubMed  CAS  Google Scholar 

  39. Gelderblom H, Verweij J, van Zomeren DM, et al. Influence of Cremophor EL on the bioavailability of intraperitoneal paclitaxel. Clin Cancer Res 2002; 8:1237–41

    PubMed  CAS  Google Scholar 

  40. Mross K, Holländer N, Hauns B, et al. The pharmacokinetics of a 1-h paclitaxel infusion. Cancer Chemother Pharmacol 2000; 45:463–70

    Article  PubMed  CAS  Google Scholar 

  41. Nannan Panday VR, ten Bokkel Huinink WW, Vermorken JB, et al. Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion. Pharmacol Res 1999; 40:67–74

    Article  Google Scholar 

  42. Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995; 13:180–90

    PubMed  CAS  Google Scholar 

  43. Huizing MT, Keung ACF, Rosing H, et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 1993; 11:2127–35

    PubMed  CAS  Google Scholar 

  44. Leal BZ, Meltz ML, Mohan N, et al. Interaction of hyperthermia with Taxol in human MCF-7 breast adenocarcinoma cells. Int J Hyperthermia 1999; 15:225–36

    Article  PubMed  CAS  Google Scholar 

  45. Rietbroek RC, Katschinski DM, Reijers MH, et al. Lack of thermal enhancement for taxanes in vitro. Int J Hyperthermia 1997; 13:525–33

    Article  PubMed  CAS  Google Scholar 

  46. Knox JD, Mitchel RE, Brown DL. Effects of taxol and taxol/hyperthermia treatments on the functional polarization of cytotoxic T lymphocytes. Cell Motil Cytoskeleton 1993; 24:129–38

    Article  PubMed  CAS  Google Scholar 

  47. van Bree C, Savoneije JH, Franken NA, et al. The effect of p53-function on the sensitivity to paclitaxel with or without hyperthermia in human colorectal carcinoma cells. Int J Oncol 2000; 16:739–44

    PubMed  Google Scholar 

  48. Othman T, Goto S, Lee JB, et al. Hyperthermic enhancement of the apoptotic and antiproliferative activities of paclitaxel. Pharmacology 2001; 62:208–12

    Article  PubMed  CAS  Google Scholar 

  49. Cividalli A, Cruciani G, Livdi E, et al. Hyperthermia enhances the response of paclitaxel and radiation in a mouse adenocarcinoma. Int J Radiat Oncol Biol Phys 1999; 44:407–12

    PubMed  CAS  Google Scholar 

  50. Cividalli A, Livdi E, Ceciarelli F, et al. Hyperthermia and paclitaxel-epirubicin chemotherapy: enhanced cytotoxic effect in a murine mammary adenocarcinoma. Int J Hyperthermia 2000; 16:61–71

    Article  PubMed  CAS  Google Scholar 

  51. Sharma D, Chelvi TP, Kaur J, et al. Thermosensitive liposomal taxol formulation: heat-mediated targeted drug delivery in murine melanoma. Melanoma Res 1998; 8:240–4

    Article  PubMed  CAS  Google Scholar 

  52. Mohamed F, Marchettini P, Stuart OA, et al. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol 2003; 10:463–8

    Article  PubMed  Google Scholar 

  53. Hager ED, Dziambor H, Hohmann D, et al. Intraperitoneal hyperthermic perfusion chemotherapy of patients with chemotherapy-resistant peritoneal disseminated ovarian cancer. Int J Gynecol Cancer 2001; 11(suppl. 1):57–63

    Article  PubMed  Google Scholar 

  54. Piso P, Dahlke M-H, Loss M, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis. World J Surg Oncol 2004; 2:21–8

    Article  PubMed  Google Scholar 

  55. Ryu KS, Kim JH, Ko HS, et al. Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol Oncol 2004; 94:325–32

    Article  PubMed  CAS  Google Scholar 

  56. Zanon C, Clara R, Chiappino I, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg 2004; 28:1040–5

    Article  PubMed  Google Scholar 

  57. Gori J, Castano R, Toziano M, et al. Intraperitoneal hyperthermic chemotherapy in ovarian cancer. Int J Gynecol Cancer 2005; 15:233–9

    Article  PubMed  CAS  Google Scholar 

  58. Raspagliesi F, Kusamara S, Campos, et al. Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: the experience of National Cancer Institute of Milan. Eur J Surg Oncol 2006; 32:671–5

    Article  PubMed  CAS  Google Scholar 

  59. Helm CW, Randall-Whites L, Martin RS III, et al. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecol Oncol 2007; 105:90–6

    Article  PubMed  CAS  Google Scholar 

  60. Rufian S, Munoz-Casares FC, Briceno J, et al. Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent and primary ovarian cancer. J Surg Oncol 2006; 94:316–24

    Article  PubMed  Google Scholar 

  61. Bae JH, Lee JM, Ryu KS, et al. Treatment of ovarian cancer with paclitaxel or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. Gynecol Oncol 2007; 106:193–209

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, University Hospital, Crete University Medical School, P.O. Box 1352, 71 110, Herakleion, Greece

    Eelco de Bree MD, Dimitris Filis MD, John Romanos MD, Maria Melisssourgaki, Markos Daskalakis MD, Maria Pilatou, Elias Sanidas MD, Panagiotis Taflampas MD & Dimitris D. Tsiftsis MD

  2. Department of Pharmacy and Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Louwesweg 6, 1066, CE, Amsterdam, The Netherlands

    Hilde Rosing PhD & Jos H. Beijnen PhD

  3. Department of Medical Oncology, University Hospital, Crete University Medical School, P.O. Box 1352, 71 110, Herakleion, Greece

    Konstantinos Kalbakis MD

Authors
  1. Eelco de Bree MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hilde Rosing PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dimitris Filis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John Romanos MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maria Melisssourgaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Markos Daskalakis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Maria Pilatou
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Elias Sanidas MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Panagiotis Taflampas MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Konstantinos Kalbakis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jos H. Beijnen PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Dimitris D. Tsiftsis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eelco de Bree MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Bree, E., Rosing, H., Filis, D. et al. Cytoreductive Surgery and Intraoperative Hyperthermic Intraperitoneal Chemotherapy with Paclitaxel: A Clinical and Pharmacokinetic Study. Ann Surg Oncol 15, 1183–1192 (2008). https://doi.org/10.1245/s10434-007-9792-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-007-9792-y

Keywords

Search

Navigation